© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Hematology
Prognostic Tool Predicts Length of Watch and Wait Period in CLL
April 10, 2020
The appropriate gap between diagnosis of chronic lymphocytic leukemia and treatment is now clearer as a new prognostic tool, IPS-E, that can predict the length of “watch and wait” has been introduced, according to a press release from the American Society of Hematology.
Evaluating Older Patients With Acute Myeloid Leukemia in SIERRA Trial
April 08, 2020
Rajneesh Nath, MD, discusses the rationale for phase III SIERRA trial, which evaluated the anti-CD45 monoclonal antibody apamistamab followed by fludarabine/total body irradiation and allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia.
FDA Grants Pembrolizumab Priority Review for TMB-High Tumors
April 07, 2020
The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.
Options for Treating Relapsed/Refractory Follicular Lymphoma
April 03, 2020
Sonali M. Smith, MD, discusses how to handle patients with follicular lymphoma when they relapse, especially if they are early progressors.
Early FCR Lacks Evidence to Change Standard Watch & Wait in Stage Binet A High-Risk CLL
April 02, 2020
Although fludarabine, cyclophosphamide, and rituximab may be efficient in inducing remission for the treatment of patients with Binet A high-risk chronic lymphocytic leukemia, recent data published in Leukemia suggest there is no evidence that this would be better than the current standard of care, which is the “watch and wait” approach.
FDA Priority Review Granted to Remestemcel-L for Pediatric Steroid-Refractory Acute GVHD
April 02, 2020
The FDA has granted a priority review to a Biologics License Application for remestemcel-L, an allogeneic cell therapy for the treatment of children with steroid-refractory acute graft-versus-host disease, according to a press release from Mesoblast Limited.
Acalabrutinib Appears Tolerable in Chronic Lymphocytic Leukemia
April 02, 2020
Jeff P. Sharman, MD, discusses the secondary end points from the phase III ELEVATE-TN trial, which evaluated the role of acalabrutinib, either as a single agent or in combination with obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.
FDA Grants Fast Track Designation for ME-401 in Relapsed/Refractory FL
April 01, 2020
The FDA has granted Fast Track Therapy designation to ME-401, an investigational selective oral inhibitor of phosphatidylinositol 3-kinase inhibitor as treatment of patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.
Sponsored: The Evolving Role of Stem Cell Transplant in Older AML Patients
April 01, 2020
Experts discuss the phase III SIERRA trial, which recently demonstrated durable complete responses in patients with acute myeloid leukemia
Chemotherapy Toxicity Correlates With Nutritional Factors in Solid Tumors
March 30, 2020
An association was found between a lower risk of grade 3 or higher chemotherapy toxicity with higher body mass indexes and normal albumin, a protein made in the liver, levels in older adult patients with solid tumors, according to an analysis of a prospective, multicenter study.